VYJUVEK Revenue Jumps 30% to $127.3M as Board Authorizes $400M Buyback
KRYS sits 69% above its 52-week low of $184.02.
Summary
Q3 product revenue rose 30% to $127.3M from $97.8M a year ago, with gross margin at 94% and net income of $63.1M, or $2.05 per diluted share. The board authorized up to $400M of buybacks, which management said it expects to execute opportunistically over the next two years, and the balance sheet holds $1.2 billion in cash and investments. The quarter's headline number is the buyback: at roughly a $9.8B market cap it is a meaningful capital-return commitment for a company that has been reinvesting everything into pipeline and European launch. The offset is pipeline timing slippage — KB801 enrollment in EMERALD-1 is running slower than planned with top-line now in 2027, KB803's last patient visit moved to February 2027, and KB407 interim data slid to the first half of 2027. VYJUVEK pricing is now settled in Germany and Italy, with an Italy launch expected in early 2027 and a Spain decision later this year. FY2026 non-GAAP combined R&D and SG&A guidance is $155.0-$165.0M; the 8:30 am ET call will carry the detail.
At the time of this announcement, KRYS was trading at $311.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.8B. The 52-week trading range was $184.02 to $382.54. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.